echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zai Lab's first anti-infective new drug listing application was accepted by the National Medical Products Administration

    Zai Lab's first anti-infective new drug listing application was accepted by the National Medical Products Administration

    • Last Update: 2020-02-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On February 10, 2020, zaiding pharmaceutical announced that the State Drug Administration has accepted its application for marketing new drugs omadacycline toluene sulfonate for the treatment of community-acquired bacterial pneumonia (CaBP) and acute bacterial skin and skin structural infection (absssi) Dr Du Ying, founder and CEO of zaiding pharmaceutical, said: "the acceptance of the application for listing of new drugs means that we have taken another important step towards becoming a fully integrated biomedical company This is our third product listing application submitted to the State Drug Administration, and also our first anti infective new drug listing application, which shows our pipeline strength in the field of treatment beyond cancer Due to the increasingly serious problem of bacterial resistance, there is still a huge unmet demand in the field of anti infection in China, and patients need innovative antibiotics Dr Harald Reinhart, chief medical officer in the field of autoimmunity and anti infection of zaiding medicine, added: "omacrine toluene sulfonate has broad-spectrum antibacterial activity and high activity against drug-resistant strains, which is suitable for the treatment of Chinese patients with CaBP and absssi Olmacycline toluenesulfonate has two dosage forms, i.e intravenous infusion and oral administration It can provide a sequential intravenous oral treatment scheme, which can help patients greatly reduce the number of days in hospital and reduce the risk of nosocomial infection At present, there is limited choice for the treatment of drug-resistant strains in China As an innovative antibiotic, olmecycline mesylate can solve the unmet medical needs Olmacycline toluene sulfonate was initially developed by paratek pharmaceuticals, a partner of zaiding pharmaceutical According to a comprehensive clinical study involving more than 2000 patients, the US Food and Drug Administration (FDA) approved its listing application for CaBP and absssi in October 2018 The State Food and drug administration has included olmacycline toluenesulfonate into a class of new drugs, which will be produced in China in the future About omacrine toluenesulfonate omacrine toluenesulfonate (nuzyra ®) is a new tetracycline designed to overcome tetracycline resistance and has a broad spectrum of antimicrobial activity, including Gram-positive bacteria, Gram-negative bacteria, atypical pathogens and a variety of drug-resistant strains Nuzyra was launched in the United States in February 2019 as a daily oral and intravenous antibiotic for adults with CaBP and absssi About zaiding pharmaceutical zaiding Pharmaceutical (NASDAQ Code: zlab) is an innovative biopharmaceutical company based on China and global operation, committed to providing innovative drugs for patients with cancer, autoimmune and infectious diseases in China and the world The company's experienced team has established strategic cooperation with the world's leading biopharmaceutical companies to create a series of candidate innovative drugs to meet the rapid growth of China's pharmaceutical market and unmet global medical needs The vision of zaiding pharmaceutical is to become a comprehensive and innovative biopharmaceutical company, to develop, produce and sell products of independent research and development and partners, and to work hard for the promotion of human health and well-being all over the world Source: zaiding medicine sprouts
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.